AD/PD Lumipulse p-tau217 analysis of blood samples
This study investigates a new blood test, the Lumipulse assay, that predicts cognitive decline and aligns with imaging results. It provides a less invasive, cost-effective way to detect Alzheimer’s risk and track disease progression, enablingng earlier and better treatment planning.
Research Summary
As therapies targeting amyloid become more available, there is a growing need for simple and accessible tools to identify those at risk for Alzheimer’s disease (AD). Current methods, like PET scans and cerebrospinal fluid (CSF) analysis, are expensive or invasive. This study investigates a new blood test, the Lumipulse assay, which measures proteins (Aβ42/Aβ40, P-Tau217, NfL and GFAP) associated with amyloid plaques—a key feature of AD. Tested in over 600 participants, the assay’s ability to predict cognitive decline and align with imaging results could provide a less invasive, cost-effective way to detect Alzheimer’s risk and track disease progression, enabling earlier and better treatment planning.
